---  
layout: startup_page  
title: "Autobahn Therapeutics"  
id: "autobahntx.com"  
permalink: "/autobahntherapeuticsautobahntx.com07242024/"  
website: "https://www.autobahntx.com"  
funding_round: "Series C"  
funding_amount: "$100M"  
investors: "Newpath Partners, Canaan Partners, Monograph Capital, Insight Partners, ARCH Venture Partners, Blue Owl Healthcare Opportunities, BVF Partners, Invus, Samsara BioCapital, Biogen, Bristol Myers Squibb, Pfizer Ventures, Section 32, Alexandria Venture Investments, GT Healthcare Capital Partners"  
about: "Autobahn Therapeutics is a biotechnology company developing restorative treatments for neuropsychiatric and neuroimmunologic disorders. Their pipeline is led by ABX-002, a thyroid hormone receptor beta agonist for depression, and ABX-101, an S1P receptor modulator for neuroimmunologic disorders. The company leverages a brain-targeting chemistry platform to enhance drug concentrations in the brain for improved efficacy."  
markets: "Biotechnology, Pharmaceuticals, Neuropsychiatry, Neuroimmunology"  
hq: "San Diego, California, United States"  
founded_year: "2017"  
linkedin: "https://www.linkedin.com/company/autobahn-therapeutics-inc"  
twitter: ""  
instagram: ""  
facebook: ""  
crunchbase: "https://www.crunchbase.com/organization/autobahn-therapeutics"  
pitchbook: "https://pitchbook.com/profiles/company/435922-57"  

date_display: "24-Jul-2024"  
date: "2024-07-24"

# SEO Optimization  
meta_title: "Autobahn Therapeutics - Series C Funding ($100M)"  
meta_description: "Autobahn Therapeutics, Autobahn Therapeutics is a biotechnology company developing restorative treatments for neuropsychiatric and neuroimmunologic disorders. Their pipeline..."  
meta_keywords: "Autobahn Therapeutics, Biotechnology, Pharmaceuticals, Neuropsychiatry, Neuroimmunology, Series C funding"  
canonical_url: "https://startup.projectstartups.com/autobahntherapeuticsautobahntx.com07242024/"  
---